A Sulfur Containing Melanogenesis Substrate, -Pr-4--CAP As a Potential Source for Selective Chemoimmunotherapy of Malignant Melanoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 29

PMID 36982309

Authors

Yasuaki Tamura

Akira Ito

Kazumasa Wakamatsu

Toshihiko Torigoe

Hiroyuki Honda

Shosuke Ito

Kowichi Jimbow

Affiliations

Soon will be listed here.

Abstract

-propionyl-4--cysteaminylphenol (-Pr-4--CAP) is a substrate for tyrosinase, which is a melanin biosynthesis enzyme and has been shown to be selectively incorporated into melanoma cells. It was found to cause selective cytotoxicity against melanocytes and melanoma cells after selective incorporation, resulting in the induction of anti-melanoma immunity. However, the underlying mechanisms for the induction of anti-melanoma immunity remain unclear. This study aimed to elucidate the cellular mechanism for the induction of anti-melanoma immunity and clarify whether -Pr-4--CAP administration could be a new immunotherapeutic approach against melanoma, including local recurrence and distant metastasis. A T cell depletion assay was used for the identification of the effector cells responsible for -Pr-4--CAP-mediated anti-melanoma immunity. A cross-presentation assay was carried out by using -Pr-4--CAP-treated B16-OVA melanoma-loaded bone marrow-derived dendritic cells (BMDCs) and OVA-specific T cells. Administration of -Pr-4--CAP induced CD8 T cell-dependent anti-melanoma immunity and inhibited the growth of challenged B16F1 melanoma cells, indicating that the administration of -Pr-4--CAP can be a prophylactic therapy against recurrence and metastasis of melanoma. Moreover, intratumoral injection of -Pr-4--CAP in combination with BMDCs augmented the tumor growth inhibition when compared with administration of -Pr-4--CAP alone. BMDCs cross-presented a melanoma-specific antigen to CD8 T cells through -Pr-4--CAP-mediated melanoma cell death. Combination therapy using -Pr-4--CAP and BMDCs elicited a superior anti-melanoma effect. These results suggest that the administration of -Pr-4--CAP could be a new strategy for the prevention of local recurrence and distant metastasis of melanoma.

References

Yamada I, Seki S, Matsubara O, Ito S, Suzuki S, Kasuga T . The cytotoxicity of cysteinylcatechols and related compounds to human melanoma cells in vitro. J Invest Dermatol. 1987; 88(5):538-40. DOI: 10.1111/1523-1747.ep12470098. View

Srivastava P, Menoret A, Basu S, Binder R, McQuade K . Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity. 1998; 8(6):657-65. DOI: 10.1016/s1074-7613(00)80570-1. View

Pankovich J, Jimbow K, Ito S . 4-S-cysteaminylphenol and its analogues as substrates for tyrosinase and monoamine oxidase. Pigment Cell Res. 1990; 3(3):146-9. DOI: 10.1111/j.1600-0749.1990.tb00279.x. View

Wakamatsu K, Ito A, Tamura Y, Hida T, Kamiya T, Torigoe T . Molecular Events in the Melanogenesis Cascade as Novel Melanoma-Targeted Small Molecules: Principle and Development. Cancers (Basel). 2022; 14(22). PMC: 9688330. DOI: 10.3390/cancers14225588. View

Inoue S, Ito S, Wakamatsu K, Jimbow K, Fujita K . Mechanism of growth inhibition of melanoma cells by 4-S-cysteaminylphenol and its analogues. Biochem Pharmacol. 1990; 39(6):1077-83. DOI: 10.1016/0006-2952(90)90287-u. View

Tandon M, Thomas P, Shokravi M, Singh S, Samra S, Chang D . Synthesis and antitumour effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminylphenol. Biochem Pharmacol. 1998; 55(12):2023-9. DOI: 10.1016/s0006-2952(98)00090-2. View

Takada T, Yamashita T, Sato M, Sato A, Ono I, Tamura Y . Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy. J Biomed Biotechnol. 2009; 2009:457936. PMC: 2760320. DOI: 10.1155/2009/457936. View

Thomas P, Kishi H, Cao H, Ota M, Yamashita T, Singh S . Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs. J Invest Dermatol. 1999; 113(6):928-34. DOI: 10.1046/j.1523-1747.1999.00781.x. View

Alena F, Iwashina T, Gili A, Jimbow K . Selective in vivo accumulation of N-acetyl-4-S-cysteaminylphenol in B16F10 murine melanoma and enhancement of its in vitro and in vivo antimelanoma effect by combination of buthionine sulfoximine. Cancer Res. 1994; 54(10):2661-6. View

10.

Uhara H . Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. Int J Clin Oncol. 2018; 24(12):1508-1514. DOI: 10.1007/s10147-018-1246-y. View

11.

Ishii-Osai Y, Yamashita T, Tamura Y, Sato N, Ito A, Honda H . N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model. J Dermatol Sci. 2012; 67(1):51-60. DOI: 10.1016/j.jdermsci.2012.04.009. View

12.

Shah D, Dronca R . Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc. 2014; 89(4):504-19. PMC: 4034544. DOI: 10.1016/j.mayocp.2014.02.002. View

13.

Gili A, Thomas P, Ota M, Jimbow K . Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity. Melanoma Res. 2000; 10(1):9-15. View

14.

Sato A, Tamura Y, Sato N, Yamashita T, Takada T, Sato M . Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release. Cancer Sci. 2010; 101(9):1939-46. PMC: 11159338. DOI: 10.1111/j.1349-7006.2010.01623.x. View

15.

Ito Y, Jimbow K . Selective cytotoxicity of 4-S-cysteaminylphenol on follicular melanocytes of the black mouse: rational basis for its application to melanoma chemotherapy. Cancer Res. 1987; 47(12):3278-84. View

16.

Jimbow K, Iwashina T, Alena F, Yamada K, Pankovich J, Umemura T . Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for malignant melanoma. J Invest Dermatol. 1993; 100(2 Suppl):231S-238S. View

17.

Pankovich J, Jimbow K . Tyrosine transport in a human melanoma cell line as a basis for selective transport of cytotoxic analogues. Biochem J. 1991; 280 ( Pt 3):721-5. PMC: 1130513. DOI: 10.1042/bj2800721. View

18.

Sato M, Yamashita T, Ohkura M, Osai Y, Sato A, Takada T . N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells. J Invest Dermatol. 2009; 129(9):2233-41. DOI: 10.1038/jid.2009.39. View

19.

Ito A, Honda H, Kobayashi T . Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol Immunother. 2005; 55(3):320-8. PMC: 11030207. DOI: 10.1007/s00262-005-0049-y. View

20.

Miura S, Ueda T, Jimbow K, Ito S, Fujita K . Synthesis of cysteinylphenol, cysteaminylphenol, and related compounds, and in vivo evaluation of antimelanoma effect. Arch Dermatol Res. 1987; 279(4):219-25. DOI: 10.1007/BF00417318. View